Mitsubishi Tanabe Pharma Corporation (MTPC) and Shionogi & Co., Ltd. reached an agreement to transfer the global rights for RADICAVA to Shionogi. This transfer includes all rights in Japan, the United States, and Canada.

To facilitate the transition, Mitsubishi Tanabe Pharma America, Inc. (MTPA) will form a new U.S.-based entity dedicated to the RADICAVA business, which Shionogi Inc. will subsequently acquire as a wholly owned subsidiary.

"As the company that helped bring RADICAVA to patients in the United States and Canada, we are incredibly proud of the impact this therapy has had on the ALS community," said Yasutoshi Kawakami, President, Tanabe Pharma America.

"By transitioning the RADICAVA® business to Shionogi, we believe the product is well positioned to continue reaching patients and caregivers who rely on it, while Tanabe Pharma America sharpens its focus on advancing future therapies."